Roche Holding AG pharmaceuticals CEO Teresa Graham said she remains enthusiastic about the opportunity for new drugs in Alzheimer’s disease, encouraged by Roche’s late-stage pipeline across therapeutic areas, and concerned about the European innovation landscape, in one of her first appearances since assuming the leadership role.
Graham took over the top pharma role at Roche in March, succeeding Bill Anderson, who left the company last year and was appointed CEO of Bayer AG. The transition comes amid a broader leadership shakeup at Roche, with CEO Severin Schwan also stepping down this year to be succeeded by Thomas Shinecker. While Graham has had a nearly 20-year career at Roche, working most recently as head of global product strategy, she hasn’t had as high of a public profile as some industry executives do before stepping into a CEO type role, in part because of the company’s diversified business model
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?